Intermediate stage hepatocellular carcinoma: a summary review

Area of Science:

• Hepatology
• Oncology
• Medical Imaging

Background:

• Intermediate stage hepatocellular carcinoma (HCC) represents the largest patient group, characterized by significant heterogeneity in liver function, tumor number, and size.
• Transarterial chemo-embolization (TACE) is a common treatment for intermediate HCC, used in 50-60% of cases, with varying international guideline considerations.
• Existing tumor response assessment methods show poor correlation with actual patient benefit in HCC, necessitating improved prognostic tools.

Purpose of the Study:

• To summarize current challenges in managing intermediate stage HCC.
• To explore future directions and potential new therapeutic options beyond TACE.
• To emphasize the need for better prognostic scores for treatment allocation and decision-making.

Main Methods:

• Review of real-world clinical data on TACE efficacy in intermediate HCC.
• Analysis of international guidelines and epidemiological differences in HCC management.
• Discussion of limitations in current tumor response assessment criteria and scoring systems.

Main Results:

• TACE is a widely applied but imperfect treatment for intermediate HCC.
• Significant heterogeneity exists within intermediate HCC, complicating treatment selection.
• Current assessment methods for treatment response in HCC are inadequate for predicting clinical benefit.

Conclusions:

• Intermediate stage HCC patients require improved prognostic scores for accurate clinical prediction and decision-making.
• Further research into multimodal treatment regimens beyond TACE is crucial.
• Addressing the heterogeneity and assessment limitations is key to advancing intermediate HCC management.